The Economist2d
Wegovy hits the People’s Republic, at last
But for a long time China’s people struggled to get hold of Wegovy because the country’s regulators had not approved it. Some ...
Is Novo Nordisk Stock a Buy?
Few companies garner as much reliable attention as Novo Nordisk ( NVO) does these days. With a bull market coinciding with a ...
Eli Lilly and Novo Nordisk’s Obesity Moat Just Got Stronger
Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.
Wegovy costs $1,349 in the US vs. $92 in the UK. Why are weight loss drugs so pricey?
About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...
Novo Nordisk Is Scaling Back Its Hiring Spree in Denmark
Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...
Novo Nordisk’s Wegovy launches in China, offering obesity drug at a fraction of US prices
According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, ...
Novo Nordisk sells hit weight-loss drug in China—at fraction of US price
Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a ...
Benzinga.com12d
Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost
Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than ...
Is Novo Nordisk Stock a Buy Right Now?
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
Exclusive-Thousands turn to Wegovy copies each month as FDA considers shortage status
More than 200,000 prescriptions for copies of Novo Nordisk's weight-loss drug Wegovy are getting filled by U.S. patients each ...